Skip to main content
Back
Watch Compare

Pharma-Bio Serv, Inc.

Data quality: 100%
PBSV
OTC Services Engineering & Management Services
$0.50
$0.00 (0.00%)
Mkt Cap: 11.45 M
Price
$0.50
Mkt Cap
11.45 M
Day Range
$0.49 — $0.49
52-Week Range
$0.40 — $1.36
Volume
7,501
Open $0.49
50D / 200D Avg
$0.53
5.30% below
50D / 200D Avg
$0.57
12.05% below

Quick Summary

Key Takeaways

Revenue declined -18.21% annually over 5 years
Negative free cash flow of -184,594.0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12.87%
Capital efficient — spends only 0.10% of revenue on capex

Growth

Revenue Growth (5Y)
-18.21%
Below sector avg (3.99%)
Revenue (1Y)-5.34%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-0.69%
Above sector avg (-15.95%)
ROIC-4.56%
Net Margin-0.86%
Op. Margin-7.25%

Safety

Debt / Equity
N/A
Current Ratio4.03
Interest CoverageN/A

Valuation

PE (TTM)
-150.39
Below sector avg (-1.17)
P/B Ratio1.12
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Services sector median (502 peers)
Metric Stock Sector Median
P/E -150.4 -1.2
P/B 1.1 1.4
ROE % -0.7 -16.0
Net Margin % -0.9 -19.4
Rev Growth 5Y % -18.2 4.0
D/E — 0.4

All Fundamental Metrics
Growth
Revenue Growth (1Y) -5.34% Revenue Growth (3Y) -27.19%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -18.21% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 8.82 M Net Income (TTM) -76,139.0
ROE -0.69% ROA -0.56%
Gross Margin 32.46% Operating Margin -7.25%
Net Margin -0.86% Free Cash Flow (TTM) -184,594.0
ROIC -4.56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.03
Interest Coverage N/A Asset Turnover 0.65
Working Capital 10.01 M Tangible Book Value 10.24 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -150.39 Forward P/E N/A
P/B Ratio 1.12 P/S Ratio 1.30
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1.61%
Market Cap 11.45 M Enterprise Value 11.45 M
Per Share
EPS (Diluted TTM) 0.00 Revenue / Share 0.39
FCF / Share -0.01 OCF / Share -0.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.10% FCF Conversion 242.44%
SBC-Adj. FCF -223,893 Growth Momentum 12.87

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9.00 M 9.51 M 16.98 M 19.40 M 20.12 M
Net Income -100,463.0 -777,619.0 1.31 M 1.01 M -2.09 M
EPS (Diluted) 0.00 -0.03 — — —
Gross Profit 2.91 M 2.52 M 5.07 M 4.88 M 5.36 M
Operating Income -637,662.0 -1.29 M 1.12 M 1.17 M -3.85 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses 3.55 M 3.80 M 3.95 M 3.71 M 9.21 M
D&A 59,866.0 23,311.0 48,086.0 51,107.0 72,728.0
Interest Expense — — — — —
Income Tax 6,203.0 22,171.0 377,307.0 181,679.0 213,246.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13.65 M 16.29 M 19.90 M 20.65 M 23.92 M
Total Liabilities 1.74 M 2.58 M 3.78 M 4.09 M 5.01 M
Shareholders' Equity 11.91 M 13.72 M 16.13 M 16.56 M 18.91 M
Total Debt — — — — —
Cash & Equivalents — — — 14.46 M 17.47 M
Current Assets 13.39 M 15.70 M 19.40 M 19.94 M 22.82 M
Current Liabilities 1.74 M 1.89 M 2.15 M 2.11 M 2.65 M